Abstract
The activin-like kinases are a family of kinases that play important roles in a variety of disease states. Of this class of kinases, ALK2, has been shown by a gain-of-function to be the primary driver of the childhood skeletal disease fibrodysplasia ossificans progressiva (FOP) and more recently the pediatric cancer diffuse intrinsic pontine glioma (DIPG). Herein, we report our efforts to identify a novel imidazo[1,2-a]pyridine scaffold as potent inhibitors of ALK2 with good in vivo pharmacokinetic properties suitable for future animal studies.
Original language | English (US) |
---|---|
Article number | 127418 |
Journal | Bioorganic and Medicinal Chemistry Letters |
Volume | 30 |
Issue number | 18 |
DOIs | |
State | Published - Sep 15 2020 |
Keywords
- ALK2
- ALK3
- Activin-like kinase inhibitors
- BMP inhibitors
ASJC Scopus subject areas
- Biochemistry
- Molecular Medicine
- Molecular Biology
- Pharmaceutical Science
- Drug Discovery
- Clinical Biochemistry
- Organic Chemistry